德意志银行-xx医疗行业月度跟踪-20170810-deutschebank-chinahealthcare：monthlyplasmatracker：june2017.pdfVIP

China Healthcare Deutsche Bank Markets Research Asia Industry Date China China Healthcare 10 August 2017 Hong Kong Health Care Industry Update Pharmaceuticals / Biotechnology Monthly plasma tracker: June 2017 Jack Hu, PhD Growth decelerated in 2Q17; domestic players lagged Albumin approval volume grew 16% YoY in 2Q17, compared with %/20% Research Analyst in 1Q17/2016, respectively. MNCs grew 29% YoY in 2Q17 vs. 18%/15% in +852- 03 6208 1Q17/2016, respectively. However, growth of domestic companies dropped to -2% YoY in 2Q17 from 30%/28% in 1Q17/2016. Bellwethers CBPO and Hualan Top picks grew -13% and 59% YoY, respectively, in 2Q17 vs. %/9% in 1Q17. Hengrui Medicine (600276.SS),CNY50.75 Buy Universal Medical (2666.HK),HKD6.37 Buy MNCs significantly outperformed; mixed performance from domestic players Sino Buy Baxalta, Grifols and Hualan delivered exceptional growth of 97%, 46% and 59% Biopharmaceutical (1177.HK),HKD6.98 YoY in 2Q17 vs. -5%, 14% and 9% in 1Q17. In comparison, growth of CSL, Source: Deutsche Bank Octapharma and CBPO decelerated to 5%, -10% and -13% YoY in 2Q17 vs. 38%, Compani